However, there is still a lack of studies on the relationship between the on-statin Lp(a) levels or the change of Lp(a) levels and the recurrence risk of vascular events in patients with AIS in a secondary prevention setting. The gene discussed is LPA; the disease is androgen insensitivity syndrome.